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Abstract: PURPOSE Voluntary salt iodization at 50 mg/kg salt ensures adequate iodine nutrition in
Swedish school-aged children, but iodine status in pregnant women is uncertain. METHODS We con-
ducted a cross-sectional national study of 743 pregnant women, at median gestational age of 23 weeks
(IQR 9, 38), recruited from maternal health care centers. We measured: urinary iodine concentration
(UIC) and urinary creatinine concentration in spot urine samples; thyroglobulin (Tg), thyroid-stimulating
hormone (TSH), and total thyroxine (tT4) on dried blood spots (DBS); and thyreoperoxidase antibodies
in serum samples. Data on dietary supplement use were obtained, and women were classified as sup-
plement users (consuming multivitamins containing ฀ 150 µg iodine/day) and non-supplement users (no
supplements or < 150 µg iodine/day from supplements). RESULTS Overall median UIC [bootstrapped
95% confidence interval (CI)] was 101 µg/L (95, 108; n = 737): 149 µg/L (132, 164) in supplement users
(n = 253) and 85 µg/L (79, 92) in non-supplement users (n = 440) (p < 0.001). Overall geometric mean
DBS-Tg (95% CI) was 22.1 ฀g/L (20.8, 23.5; n = 675) and the prevalence of elevated DBS-Tg was 19%.
DBS-Tg was lower in supplement users (n = 229) than in non-supplement users (n = 405) (19.1 vs 24.4
฀g/L, p < 0.001). DBS-TSH, DBS-tT4, and S-TPOab positivity did not differ between the two groups.
CONCLUSIONS Pregnant women in Sweden have inadequate iodine nutrition. Women not taking io-
dine supplements containing ฀ 150 µg iodine/day are affected by mild iodine deficiency and are at higher
risk for increased thyroid activity, while maintaining euthyroidism. Iodine intake should be improved in
women both before and after conception by promotion of iodized salt instead of non-iodized salt. We
urge regular monitoring of iodine status in the general Swedish population, as well as in risk groups.
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Abstract
Purpose Voluntary salt iodization at 50 mg/kg salt ensures adequate iodine nutrition in Swedish school-aged children, but 
iodine status in pregnant women is uncertain.
Methods We conducted a cross-sectional national study of 743 pregnant women, at median gestational age of 23 weeks 
(IQR 9, 38), recruited from maternal health care centers. We measured: urinary iodine concentration (UIC) and urinary 
creatinine concentration in spot urine samples; thyroglobulin (Tg), thyroid-stimulating hormone (TSH), and total thyroxine 
(tT4) on dried blood spots (DBS); and thyreoperoxidase antibodies in serum samples. Data on dietary supplement use were 
obtained, and women were classified as supplement users (consuming multivitamins containing ≥ 150 µg iodine/day) and 
non-supplement users (no supplements or < 150 µg iodine/day from supplements).
Results Overall median UIC [bootstrapped 95% confidence interval (CI)] was 101 µg/L (95, 108; n = 737): 149 µg/L (132, 
164) in supplement users (n = 253) and 85 µg/L (79, 92) in non-supplement users (n = 440) (p < 0.001). Overall geometric 
mean DBS-Tg (95% CI) was 22.1 μg/L (20.8, 23.5; n = 675) and the prevalence of elevated DBS-Tg was 19%. DBS-Tg was 
lower in supplement users (n = 229) than in non-supplement users (n = 405) (19.1 vs 24.4 μg/L, p < 0.001). DBS-TSH, DBS-
tT4, and S-TPOab positivity did not differ between the two groups.
Conclusions Pregnant women in Sweden have inadequate iodine nutrition. Women not taking iodine supplements contain-
ing ≥ 150 µg iodine/day are affected by mild iodine deficiency and are at higher risk for increased thyroid activity, while 
maintaining euthyroidism. Iodine intake should be improved in women both before and after conception by promotion of 
iodized salt instead of non-iodized salt. We urge regular monitoring of iodine status in the general Swedish population, as 
well as in risk groups.
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Introduction
Adequate dietary iodine is essential for the production of 
thyroid hormones. Moderate-to-severe iodine deficiency 
during pregnancy increases the risk of cognitive impair-
ment in the offspring [1–4]. Observational studies suggest 
that even mild iodine deficiency during pregnancy may 
negatively affect verbal intelligence quotient and educa-
tional level in their children [5–7], although a causal rela-
tion could not be confirmed in a recent randomized con-
trolled trial of iodine supplementation in pregnant women 
with mild iodine deficiency [8].
Pregnant women have higher iodine requirements than 
before pregnancy and are vulnerable to iodine deficiency 
due to increased thyroid hormone production, increased 
renal iodine clearance, and transplacental transfer of iodine 
to the fetus [9]. The recommended daily iodine intake for 
pregnant women is 250 μg, higher than the 150 μg/day 
recommended to non-pregnant women of reproductive age 
[10]. A median spot urinary iodine concentration (UIC) 
during pregnancy of 150–249 µg/L indicates adequate 
iodine nutrition in a population [10].
Iodine deficiency was historically endemic in Sweden 
with reported goiter prevalence up to 60% in certain areas 
[11, 12]. Swedish authorities introduced voluntary iodine 
fortification of table salt in 1936 [11, 13]. The current 
level of iodine in fortified salt is 50 mg/kg salt and has 
remained the same since 1966 [14, 15]. The first national 
monitoring of the present salt iodization program was con-
ducted in school-aged children (6–12 years) in 2007 and 
the findings implied iodine sufficiency [16, 17]: no goiter 
was observed [16] and the median UIC was 125 µg/L 
[17], within the recommended range of 100–299 µg/L 
[10, 18]. At the same time, a local study suggested mild 
iodine deficiency in the third trimester of pregnancy [19]. 
Furthermore, more than 75% of consumed salt in Swe-
den is non-iodized [personal communication with the salt 
industry, 2017], milk iodine concentration has declined 
[20], consumption of iodine-rich fish and dairy products 
is decreasing [14], and national authorities recommend 
reduced salt intake [21].
We conducted a national cross-sectional study in Sweden 
with the objectives of assessing iodine status and thyroid 
function in pregnant women and evaluating the impact of 




The sample collection period of this national cross-sectional 
study in pregnant women was August 2015 to April 2016. 
Subjects were recruited using a stratified two-stage probabil-
ity proportionate to size cluster design [10]. Stratified ran-
dom sampling was applied using the common grouping of 
the Swedish population into six regions (H regions) based on 
regional population density [22]. In the first stage, 25 mater-
nal health care (MHC) centers were recruited. The number 
of selected centers corresponded to the total population of 
each stratum. If a selected MHC center declined participa-
tion, an alternate MHC center was randomly selected with 
replacement sampling from the same stratum. From each 
MHC center, midwives recruited 30 consecutive women, 
10 from each trimester. We defined the first, second, and 
third trimesters as pregnancy weeks 1–12, 13–28, and ≥ 29, 
respectively.
Gothenburg Ethical Committee approved the study (Dnr 
095-15 and T666-15) and it was performed in compliance 
with the ethical standards laid down in the 1964 Declaration 
of Helsinki and its later amendments. All study participants 
gave their informed consent prior to their inclusion in the 
study.
Each woman provided a spot urine sample for assessment 
of UIC and urinary creatine concentration (U-creatinine) 
and a dried blood spot (DBS) sample for measurement of 
thyroglobulin (Tg), thyroid-stimulating hormone (TSH), and 
total thyroxine (tT4). A venous blood sample was obtained 
for the determination of serum thyreoperoxidase antibodies 
(S-TPOabs) in the MHC centers with capacity to handle and 
store serum samples (13 of 25 centers).
The midwives obtained information on gestational age, 
presence of multiple pregnancy, and measured weight and 
height using standard anthropometric techniques. A brief 
questionnaire, filled in by the study participants, was used to 
collect information on current smoking, use of vitamin sup-
plements, thyroid disease, and thyroid-related medication.
Subjects
All pregnant women attending one of the selected MHCs 
were eligible for the study; no exclusion criteria were 
applied.
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Methods
Women were given a plastic cup and were asked to pro-
vide ~ 20 mL of fresh midstream urine, directly after their 
routine visit to MHC. Midwives were instructed not to 
expose the urine samples to any dipsticks, due to risk of 
iodine contamination. Samples were transported in a cool 
box from the place of collection to the central laboratory. 
Aliquots of all urine samples were frozen at − 20 °C until 
analysis. Blood drops (50 μL) were collected by a finger 
prick and directly collected onto filter paper cards (IDBS-
226, Perkin Elmer, CT). The DBS cards were dried at 
room temperature, placed in sealed plastic bags, and stored 
at 4 °C until analysis or frozen at − 20 °C before analysis.
Laboratory analyses
Urinary iodine and creatinine concentration
Spot urine samples were transported and stored at − 20 °C 
until analysis. For transport shorter than 8 h, they were 
transported in room temperature, which does not influence 
their quality. UIC in spot urine samples was measured by a 
single laboratory technician at the Department of Clinical 
Nutrition at Sahlgrenska Academy, University of Goth-
enburg (Göteborg, Sweden) using the Pino modification 
of the Sandell-Kolthoff reaction [23]. The laboratory suc-
cessfully participates in the EQUIP network (US Centers 
for Disease Control and Prevention, Atlanta, GA) and is 
evaluated for analytical accuracy every 3 months. All urine 
samples were measured in duplicate and reanalyzed, if dif-
ference in absorbance was > 5% for UIC > 150 μg/L, > 10% 
for UIC 50–150 μg/L, and > 15% for UIC < 50 μg/L. Exter-
nal quality control was ensured by measuring control 
urine samples that were added to the daily sample meas-
urements. The UIC analysis was validated against induc-
tively coupled plasma mass spectrometry at the Genomics 
and Biomarkers Unit in Finland, as part of the EUthy-
roid project (Helsinki, Finland). The correlation between 
the two methods was high (linear regression: R2 = 0.875, 
p = 0.023). Adequate iodine status in pregnant women was 
defined as median UIC ≥ 150 µg/L [10].
U-creatinine was measured with a photometric method 
using Cobas from Roche Diagnostics (Stockholm, Swe-
den) at the accredited Laboratory of Clinical Chemistry at 
Sahlgrenska University Hospital, Göteborg, Sweden. The 
coefficience of variance was 4%.
Thyroglobulin concentration
DBS-serum samples were transported and stored at 
− 20 °C until analysis. For transport shorter than 8 h, 
they were transported in room temperature, which does 
not influence their quality. DBS-Tg was measured with a 
DBS-Tg sandwich enzyme-linked immunosorbent assay 
at ETH Zurich (Zurich, Switzerland) [24]. Serum control 
samples (Liquicheck Tumor Marker Control, LOT.19970 
and LOT.19980; Bio-Rad, Hercules, CA, USA) were used 
as standards for the DBS-Tg assay. In-house DBS samples 
were used for quality control and the coefficient of vari-
ance (CV) was 14% (n = 21) at 19 µg/L and 9% (n = 21) at 
67 µg/L. The assay-specific reference range for DBS-Tg in 
pregnant women was 0.3–43.5 µg/L [25].
TSH and tT4 concentrations
DBS-serum samples for TSH and Tt4 were handled at the 
same way as DBS-serum samples for Tg, described above. 
TSH and tT4 were measured in DBS samples at the Swiss 
Newborn Screening Laboratory, University Children’s Hos-
pital (Zurich, Switzerland). DBS-TSH and DBS-tT4 were 
analyzed with the use of an automated time-resolved fluoro-
immunoassay method (GSP 2021-0010; PerkinElmer Life 
Sciences, Turku, Finland) using a related GSP Neonatal 
TSH/tT4 kit (PerkinElmer Life Sciences, Turku, Finland). 
Kit-specific DBS controls were used for the analysis. The 
CV for TSH was 10% (n = 12) at 15 mU/L and 8% (n = 11) 
at 62 mU/L. For tT4, the CV was 9% (n = 12) at 40 nmol/L, 
10% (n = 12) at 100 nmol/L, and 8% (n = 12) at 158 nmol/L.
Serum thyreoperoxidase antibodies
Serum samples were transported in −  20  °C and were 
thereafter stored at − 80 °C, until analys. S-TPOabs were 
measured in serum samples at the Laboratory for Clinical 
Chemistry at Skåne University Hospital (Malmö, Sweden) 
with an electrochemoluminicence immunoassay (Cobas 
NPU20041, Roche Diagnostics, Solna, Sweden). The Labo-
ratory of Clinical Chemistry at Skåne University Hospital, 
Sweden, successfully participates in national, international 
and internal control programs, where unknown samples are 
analyzed, a process reviewed by Swedac, the Health and 
Social Care Inspectorate and by the Swedish Technician 
Research Institute. The normal reference range for S-TPOabs 
was < 34 kIE/L.
Thyroid morbidity
Kit- and laboratory-specific reference ranges were used to 
calculate the prevalence of thyroid dysfunction. We used 
trimester- and pregnancy-week-specific reference ranges. We 
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used the normal reference values defined for DBS-TSH in 
non-pregnant adults (0.1–3.7 mIU/L) for pregnant women 
in the second and third trimesters and reduced the upper 
limit to 3.0 mIU/L in the first trimester, as recommended 
by the American Thyroid Association [26]. For DBS-tT4 
in pregnant women in week 1–6, we applied the assay-
specific normal reference range for non-pregnant adults of 
65–165 nmol/L. Thereafter, we increased the non-pregnant 
upper reference limit by 5% per week, beginning with week 
7 [26]. Starting week 16, we multiplied the non-pregnant 
adult reference range by 1.5 and used the resulting range 
of 97.5–247.5 nmol/L [29]. Low or high DBS-TSH repre-
sented hyper- and hypothyroidism, respectively, and this was 
described as clinical or subclinical thyroid disease depend-
ing on whether DBS-tT4 was outside or within the refer-
ence range, respectively. Normal DBS-TSH with high or low 
DBS-tT4 was defined as isolated hyper- or hypothyroxine-
mia, respectively.
Statistical methods
The sample size of the study was determined to assess the 
median UIC with 5% precision (95% CI) [27–29]. The rec-
ommended sample size needed to accurately estimate the 
median (or geometric mean) UIC with 5% precision range 
from 389 to 473, based on an inter-individual variability 
(CV %) of 50–55% for transformed UIC data [27, 28]. A 
previous study in Swedish pregnant women [19] reported an 
inter-individual variability (CV %) for UIC of 17% for log 
data (71% for crude data), lower than estimated in the studies 
by König et al. and Karmisholdt et al. [27, 28]. However, to 
account for an assumed skewed population distribution of 
UIC and the cluster design, we aimed to enroll 750 pregnant 
women.We used Excel 2016 (Microsoft, Redmond, WA, 
USA) and SPSS version 24.0 (IBM, Armonk, NY, USA) for 
data processing and analysis. The primary outcome param-
eter of the study was UIC. Secondary outcome parameters 
were DBS-Tg, DBS-TSH, DBS-tT4, and S-TPOabs: subjects 
undergoing treatment with levothyroxine were excluded 
from the data analysis of these four outcomes.
Normality for continuous variables was assessed visu-
ally (by comparing with normal distribution, Q–Q plots, 
and box-plots) and by normality tests (Shapiro–Wilk test). 
Non-normally distributed data were log-transformed before 
data analysis. DBS-Tg fulfilled the normality criteria after 
log-transformation and is presented as geometrical mean and 
95% confidence interval (CI). Variables remaining skewed 
after log-transformation are presented as median, quartile 
(Q)1, and Q3. Non-parametric 95% CIs around the median 
were obtained using the bootstrap technique (n = 1000). UIC 
data were normally distributed after log-transformation, 
but is presented as median, interquartile range (IQR), and 
bootstrapped 95% CI for consistency with common practice. 
No outliers were removed from the descriptive data.
Women were categorized as supplement users (using sup-
plements containing ≥ 150 µg iodine/day) and non-supple-
ment users (using no supplements or supplements contain-
ing < 150 µg iodine/day). The cut-off of 150 μg was chosen 
as this is the recommended level for iodine supplementation 
during pregnancy in many countries [26, 43] and as the most 
popular multivitamin tablets in Sweden contain 75, 80,100 
and 150 μg iodine. Independent t test and ANOVA with 
Bonferroni correction were used for group comparison of 
normally distributed variables (after logarithmic transforma-
tion). Mann–Whitney test was used for group comparison 
of skewed variables. Categorical variables were compared 
with Chi-square test or Fischer’s exact test, in the case of few 
observed cases (n < 5). All statistical significance was set as 
alpha significance 0.05.
Results
We enrolled 743 pregnant women from 25 MHC centers 
(18% of all MHCs asked). The recruitment of the 25 MHC 
centers (Table  1) followed the intended plan, with one 
exception: the region with the highest population nativity 
(H1 region) contributed two out of the intended six MHC 
centers. The remaining four MHC centers were recruited 
from the H2 region, i.e. the region with the second highest 
population nativity. Subject characteristics are presented in 
Table 2. Iodine-containing supplements (≥ 150 µg iodine/
day) were used by 34.8% of the women.
The overall median UIC (IQR) was 101 µg/L (61, 182; 
n = 737) with bootstrapped 95% confidence interval (CI) 
(95, 108), without difference across trimesters (p = 0.381, 
Table  3). The UIC:U-creatinine ratio (IQR) was 0.11 
(0.07, 0.19; n = 737), with no difference across trimesters 
(p = 0.153, Table 3). The median UIC (IQR) was 149 µg/L 
(88, 253; n = 253) in supplement users (using supplements 
containing ≥ 150  µg iodine/day) and 85  µg/L (51,134; 
n = 440) in non-supplement users (using no supplements or 
supplements containing < 150 µg iodine/day) (p < 0.001). 
The bootstrapped 95% CI of median UIC was (132, 164) 
in supplement users and (79, 92) in non-supplement users 
(Fig. 1a). Levothyroxine was used by 8.9% (n = 66) of the 
women, being equally distributed among supplement and 
non-supplement users (p = 0.206). The median UIC after 
excluding those on levothyroxine treatment did not differ 
compared to the median UIC in the complete study group 
(p = 0.942, data not shown).
The overall geometric mean DBS-Tg (95% CI), after 
exclusion of subjects on levothyroxine (n = 66) was 
22.1 μg/L (20.8, 23.5; n = 675), with no difference across 
trimesters (p = 0.579, Table  3). The geometric mean 
2539European Journal of Nutrition (2020) 59:2535–2545 
1 3
DBS-Tg (95% CI) was 19.1 µg/L (17.2, 21.3, n = 229) in 
supplement users and 24.4 µg/L (22.6, 26.3, n = 405) in 
non-supplement users (p < 0.001) (Fig. 1b). The preva-
lence of elevated DBS-Tg was 19%: 13.1% among sup-
plement users and 22.5% of among non-supplement users 
(p = 0.004). After exclusion of subjects with S-TPOab 
positivity (n = 45), the geometric mean DBS-Tg was still 
lower (p = 0.002) in supplement users than in non-supple-
ment users (data not shown).The concentration of thyroid 
function parameters (DBS-TSH, DBS-tT4, and S-TPOabs) 
and the prevalence of subclinical and clinical thyroid dis-
orders after exclusion of subjects treated with levothyrox-
ine (n = 66) are presented in Table 3. The prevalence of 
thyroid dysfunction was low overall, except for isolated 
hypothyroxinemia, present in 24.8% of pregnant women 
(Table 3). When stratified for trimesters, the frequency of 
isolated hypothyroxenimia was higher and isolated hyper-
thyroxenimia lower in third trimester than in the first tri-
mester. Comparison between first and second trimester 
gave just marginal significances of the same direction, 
whereas second and third trimesters presented no differ-
ences (Table 3). Clinical thyroid disease and subclinical 
hyperthyroidism were not observed. There was no differ-
ence between supplement users and non-supplement users 
for: prevalence of levothyroxine medication (p = 0.206, 
n = 699), DBS-TSH (p = 0.633, n = 633), DBS-tT4 
(p = 0.328, n = 633), and S-TPOab positivity (p = 0.107, 
n = 318). The two groups did not differ for any of the 
three entities of thyroid morbidity observed: subclinical 
hypothyroidism (p = 1.0, n = 631), isolated hypothyroxine-
mia (p = 0.633, n = 631), and isolated hyperthyroxinemia 
(p = 0.449, n = 631). After exclusion of S-TPOab positive 
subjects (n = 45), no difference was observed between sup-
plement users and non-supplement users for DBS-TSH and 
DBS-tT4 (data not shown).
Table 1  Recruitment at Maternal Health Care (MHC) centers in Sweden based on statistically determined number of MHC centers in each H 
region
The six H regions represent geographical areas in Sweden with different population nativity (H1 with the highest nativity trough H6 with the 
lowest nativity)
Region H1 H2 H3 H4 H5 H6 Total

























Intended recruitment (n) 180 150 270 90 30 30 756
Actual recruitment (n) 60 271 263 89 30 30 743
Table 2  General characteristics of the study participants in a nation-
ally representative sample of pregnant women in Sweden
BMI body mass index, IQR interquartile range
No. of partici-
pants evaluated
Median gestational age, weeks (IQR)
 All participants 23 (9, 38) 741
 First trimester 10 (9, 11) 259
 Second trimester 24 (18, 25) 235
 Third trimester 34 (30, 36) 247
Multiple pregnancy, n (%)
 No 533 (72) 743
 Yes 23 (3)
 Unknown 187 (25)
Median BMI, kg/m2 (IQR)
 First trimester 23.8 (21.9, 26.7) 251
 Second trimester 25.3 (23.3, 28.7) 231
 Third trimester 28.4 (26.3, 31.6) 240
Smoker, n (%)
 No 719 (97)
 Yes 18 (2) 743
 Unknown 6 (1)
Dietary supplement use, n (%)
  None 376 (51) 742
 Unknown iodine content 43 (6)
 < 75 μg iodine/day 31 (4)
 75–100 μg iodine/day 34 (5)
 101–149 μg iodine/day 0 (0)
 ≥ 150 μg iodine/day 258 (35)
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Table 3  Iodine status, thyroid 
function tests and thyroid 
morbidity in a nationally 
representative sample of 
pregnant women in Sweden
No. of participants 
evaluated
p value
Median UIC μg/L (IQR)
 All participants 101 (61, 182) 737 0.381
 First trimester 105 (69, 177) 254
 Second trimester 97 (60, 181) 235
 Third trimester 100 (60, 183) 246
Median U-creatinine μg/L (IQR)
 All participants 1018 (571, 1528) 737 –a
 First trimester 1131 (665, 1696) 254
 Second trimester 860 (531, 1357) 235
 Third trimester 972 (531, 1471) 246
Median UIC:creatinine ratio (IQR)
 All participants 0.11 (0.07, 0.19) 737 0.153
 First trimester 0.10 (0.06, 0.18) 254
 Second trimester 0.11 (0.08, 0.21) 235
 Third trimester 0.11 (0.07, 0.19) 246
Geometric mean DBS-Tg, μg/L (95% CI)
 All participants 22.1 (20.8, 23.5) 675 0.579
 First trimester 22.8 (19.6, 24.3) 223
 Second trimester 22.1 (18.9, 23.5) 209
 Third trimester 23.3 (21.0, 25.9) 230
Median DBS-TSH, mU/L (IQR)
 All participants 0.7 (0.5, 1.0) 672 –a
 First trimester 0.7 (0.5, 0.9) 234
 Second trimester 0.7 (0.5, 1.0) 208
 Third trimester 0.8 (0.5, 1.0) 228
Median DBS-tT4, nmol/L (IQR)
 All participants 124 (90, 155) 672 –a
 First trimester 120 (91, 152) 234
 Second trimester 127 (91, 158) 208
 Third trimester 124 (84, 157) 228
Positive S-TPOabs, n (%)
 All participants 39 (11.6) 334
 First trimester 19 (16.6) 114
 Second trimester 11 (10.6) 104 0.100
 Third trimester 9 (7.8) 116
Clinical thyroid disease, n (%) 0 669 –
Subclinical hyperthyroidism, n (%) 0 669 –
Subclinical hypothyroidism, n (%)
 All participants 2 (0.3) 669 0.333
 First trimester 2 (0.3) 233
 Second trimester 0 208
 Third trimester 0 228
Isolated hypothyroxinemia, n (%)
 All participants 166 (24.8) 669 0.002b
 First trimester 41 (17.6) 233
 Second trimester 53 (25.5.) 208
 Third trimester 72 (31.6) 228
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Discussion
This is the first national study assessing iodine status 
and thyroid function of pregnant women in Sweden. The 
median UIC of 101 μg/L in the study population is far 
below the recommended optimal range for pregnant women 
of 150–249 μg/L [10] and the results suggest mild iodine 
deficiency.
Our results are consistent with previous data. Local and 
regional studies in pregnant women in Sweden, conducted 
more than 10 years ago [19, 30], report low UIC and ele-
vated Tg concentration, indicating that iodine intake in preg-
nant women has been insufficient over a prolonged period. 
However, the overall iodine intake in school-aged children 
is adequate. A national study in children aged 6–12 years 
conducted by our group in 2007 found a median UIC of 
125 μg/L [17], which is within the recommended range of 
100–299 μg/L [10, 18], and goiter was not observed [16].
Iodine deficiency during pregnancy is frequently 
observed despite iodine sufficiency in school-aged children, 
e.g. in Norway, Denmark, Switzerland, USA [14, 31–33]. 
A review of studies conducted simultaneously in school-
aged children and pregnant women in countries where salt 
is the main dietary source of iodine, showed that median 
UIC in pregnant women typically meets the recommended 
150 μg/L in populations where the median UIC in school-
aged children exceeds 180 μg/L [34]. However, in coun-
tries with voluntary iodization, the coverage by iodized salt 
may be incomplete. Although the data are limited (personal 
communication with the salt industry, 2017), most of the 
household salt in Sweden appears to be iodized, whereas 
processed food and food served in restaurants, an important 
salt source for working women in Sweden, seems to have 
lower coverage by iodized salt. Therefore, despite voluntary 
iodization at 50 mg/kg salt [14, 15], above the recommended 
20–40 mg/kg [10], iodine intake in Sweden is inadequate in 
pregnant women, probably due to poor coverage by iodized 
salt. A recent study conducted in populations with manda-
tory legislation and high coverage by iodized salt [35] dem-
onstrated that a well implemented salt iodization program 
ensures adequate dietary intake in all population groups. 
National recommendations in Sweden to promote iodized 
salt by the food industry are warranted as well as considera-
tion of applying this on a mandatory basis.
One-third of the women in our study consumed iodine-
containing prenatal dietary supplements containing ≥ 150 μg 
iodine/day and the median UIC in iodine supplement users 
suggested adequate iodine intake. The additional supplemen-
tal iodine may have a positive impact on the thyroid gland, 
as suggested by the lower DBS-Tg in this group compared to 
non-supplement users. However, the DBS-Tg concentration 
in supplement users was still higher than expected for an 
iodine-sufficient population (~ 10 μg/L) [25]. It is possible 
that women in Sweden have inadequate iodine intake before 
conception and iodine supplementation is not sufficient to 
normalize DBS-Tg during pregnancy. This is supported by 
the elevated DBS-Tg observed in the first trimester. It is also 
possible that other nutrient deficiencies beyond iodine (e.g. 
selenium, iron [36, 37]) interact with thyroid metabolism. 
Finally, thyroid size, reflected by DBS-Tg, may be larger in 
the Swedish population, as shown for school-aged children 
when compared with an age-matched reference international 
population [16].
The overall prevalence of isolated hypothyroxinemia 
was 25% and did not differ between supplement users and 
non-users, but was higher in third trimester (32%) compared 
with first trimester (18%). The high prevalence of isolated 
hypothyroxinemia in our population contrasts with a local 
Subjects treated with levothyroxine (n = 66) are excluded
CI confidence interval, DBS dried blood spot, IQR interquartile range, S-TPOabs serum thyreoperoxidase 
antibodies, Tg thyroglobulin, TSH thyroid-stimulating hormone, tT4 total thyroxine, UIC urinary iodine 
concentration, U-creatinine urinary creatine concentration
a Analysis between trimesters not conducted, due to lack of clinical relevance (regarding U-creatinine) or 
due to different reference range (regarding DBS-TSH and DBS-tT4)
b Analysis between trimesters for isolated hypothyroxeinemia: First-Second trimester, p = 0.044; Second-
Third trimester; p = 0.160, First-Third trimester, p < 0.001
c Analysis between trimesters for isolated hyperthyroxinemia: First-Second trimester, p = 0.048; Second-
Third trimester, p = 0.861; First-Third trimester, p = 0.027
Table 3  (continued) No. of participants 
evaluated
p value
Isolated hyperthyroxinemia, n (%)
 All participants 32 (4.8) 669 0.033c
 First trimester 18 (7.7) 233
 Second trimester 7 (3.4) 208
 Third trimester 7 (3.1) 228
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Swedish study [38], where only 2.8% of pregnant women 
presented isolated hypothyroxinemia, which was though 
measured in serum samples at median pregnancy week 18. 
The clinical importance of isolated hypothyroxinemia is 
debated; some studies indicate an association with impaired 
neurocognitive development of offspring [39], whereas oth-
ers do not [40, 41]. The use of tT4 concentration, as a proxy 
for free T4, may induce bias when estimating the prevalence 
of hypothyroxinemia. Increased estradiol production during 
pregnancy leads to elevation of thyroxine-binding globulin, 
resulting in higher tT4 despite stable or lower free T4 dur-
ing pregnancy. To compensate for this, an elevation of the 
upper limit of the reference range throughout pregnancy is 
recommended [26] and was applied in our study, but the 
precision of the lower limit of tT4 is uncertain. Furthermore, 
no reference range has specifically been defined for DBS-T4 
and DBS-TSH during pregnancy, possibly contributing to 
misclassification. Uncertainty also prevails in terms of the 
free T4 reference range during pregnancy, free T4 being 
associated with tT4. In one study [42], free T4 decreased 
from first to second trimester despite iodine supplementation 
and TSH remained stable, suggesting the decrease in free 
T4 during pregnancy may be a physiological observation. 
The same trend during pregnancy was observed in our study 
population regarding isolated hypothyroxinemia; the oppo-
site trend, though in lower prevalence, was noticed in iso-
lated hyperthyroxenemia, which was more frequent in first 
trimester (8%) than in third trimester (3%), highlighting the 
need of proper reference intervals deriving from a thyroid 
healthy, iodine sufficient population of pregnant women.
The observed mild iodine deficiency in this study raises 
the question of national recommendation in Sweden for 
iodine supplementation of 150 µg/day during pregnancy, as 
recommended in several other countries [26, 43] and as sup-
ported by World Health Organization when the coverage of 
iodized salt is incomplete [10]. Several observational stud-
ies suggest an association between mild iodine deficiency 
during fetal life and poor educational level, motor skills, 
or verbal abilities in children 3–12 years of age [5, 6, 44, 
45]. However, this was not confirmed in randomized con-
trolled trials of iodine supplementation of pregnant women 
with mild iodine deficiency [8, 42], possibly due to lower 
than expected prevalence of iodine deficiency in the popu-
lation studied in one trial [8] or due to low sample size in 
the other trial [42]. At the same time, other observational 
studies have indicated the opposite, i.e. iodine supplemen-
tation during fetal life was associated with higher risk of 
behavioral problems or poorer mental and psychomotor 
development in children [45–47]. It has been proposed that 
a sudden increase of iodine intake blocks fetal thyroid func-
tion, leading to hypothyroidism and goiter, especially in the 
case of preconceptional iodine deficiency [48]. Women with 
preconceptional iodine deficiency may handle the restricted 
available iodine more effectively during pregnancy [49]. 
Taken together, the data supporting iodine supplementation 
during pregnancy in mild ID are inconclusive. A randomized 
clinical trial of prenatal iodine supplementation is currently 
ongoing in Sweden and the results will provide valuable 
data on the consequences of mild iodine deficiency on fetal 
development [50].
We recognize the low response rate of the MHC cent-
ers (18% of all asked) as a weakness of the study, but 
the reason given for declining participation was the high 
workload of midwives, which is unlikely to be associated 
with the outcome parameters. Although only two of the 

































































Fig. 1  Median (boostrapped 95% CI) UIC (a) and geometric mean 
(95% CI) DBS-Tg (b) in pregnant women who consume a daily sup-
plement of ≥ 150 μg iodine (supplement users) vs those who consume 
no supplements or supplements containing < 150  μg iodine (non-
supplement users). Dotted line represents the lower recommended 
median UIC during pregnancy (a) and the Tg level expected in an 
iodine-sufficient population (b) [18, 28]. Mann–Whitney U test and 
unpaired t test were used to test differences between the groups. CI 
confidence interval, DBS-Tg dried blood spot thyroglobulin concen-
tration, UIC urinary iodine concentration
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region, the remaining four MHC centers were recruited 
from the region (H2) with the closest population density. 
The applied stratified cluster sampling methodology still 
ensured a representative sample of the Swedish pregnant 
population. Data on iron and selen status or other endo-
crine disruptors were not collected; we plan, however, to 
investigate the possible interaction between iodine, iron 
and selen within the framework of another study (Clinical-
Trials.gov identifier: NCT02378246). We did not study the 
locality either, as sample size for each area was small and 
we followed the WHO recommendations for monitoring of 
iodization program by clinic-based cross-sectional surveys 
(10). Besides, a comparison between the different areas 
in the country was beyond the scope of this study, as we 
aimed to set the ground for recommendations to pregnant 
women nationally.
In conclusion, adequate iodine intake in school-aged 
children does not guarantee adequate intake in risk popula-
tions, even in a country with a high level of iodine fortifi-
cation of salt. Pregnant women in Sweden have inadequate 
iodine nutrition and only 35% consume a daily supplement 
with iodine ≥ 150 μg. Women not taking iodine-containing 
supplements or supplements containing < 150 μg/day are 
exposed to mild iodine deficiency. The low iodine intake 
increases the risk of elevated thyroid activity to maintain 
euthyroidism. The long-standing national policy of uni-
versal salt iodization on a voluntary basis is not operating 
as intended and actions to improve its coverage must be 
urgently undertaken. We suggest that Swedish authorities 
encourage the food industry to use iodized salt instead of 
non-iodized salt and we urge regular monitoring of iodine 
status of the general Swedish population and of groups at 
particular risk of inadequate iodine intake, as a part of the 
national nutrition policy, supported by the National Food 
Agency. A randomized controlled trial in a population 
with mild iodine deficiency is highly warranted [50] to 
provide authorities with guidance on whether iodine sup-
plementation during pregnancy should be recommended 
or not. If the coverage of iodized salt is not improved and 
mild iodine deficiency infers mental consequences, man-
datory iodization of table salt may be considered.
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